Table 2.
Univariate Cox proportional hazards regression analysis of clinical and pathological characteristics.
| Overall survival | Cancer-specific survival | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Gender | ||||||
| Male | 1 | 1 | ||||
| Female | 0.576 | 0.214–1.553 | 0.275 | 1.041 | 0.260–4.162 | 0.955 |
| Age (years) | ||||||
| <60 | 1 | 1 | ||||
| ≥60 | 6.763 | 2.299–19.891 | <0.001 | 11.363 | 1.421–90.865 | 0.022 |
| Histologic subtype | ||||||
| Clear cell RCC | 1 | 1 | ||||
| Non-clear-cell RCC | 0.425 | 0.057–3.159 | 0.403 | 1.137 | 0.142–9.105 | 0.904 |
| Multiple primary neoplasms | ||||||
| No | 1 | 1 | ||||
| Yes | 9.398 | 4.116–21.460 | <0.001 | 6.549 | 1.637–26.192 | 0.008 |
| Type of surgery | ||||||
| Partial nephrectomy | 1 | 1 | ||||
| Radical nephrectomy | 1.904 | 0.704–5.148 | 0.205 | 1.911 | 0.394–9.269 | 0.421 |
| Surgical approach | ||||||
| Laparoscopic surgery | 1 | 1 | ||||
| Open surgery | 1.676 | 0.718–3.913 | 0.232 | 1.096 | 0.261–4.602 | 0.900 |
| IFN-α/IL-2 therapy | ||||||
| No | 1 | 1 | ||||
| Yes | 1.495 | 0.624–3.583 | 0.368 | 1.445 | 0.353–5.922 | 0.609 |
| NLR | ||||||
| <1.97 | 1 | 1 | ||||
| ≥1.97 | 4.164 | 1.545–11.226 | 0.005 | 3.950 | 0.819–19.050 | 0.087 |
Abbreviation: NLR, neutrophil-to-lymphocyte ratio. HR, hazard ratio. CI, confidence interval.